SAN DIEGO — The benefit for patients treated by an experimental blood disease drug from Acceleron Pharma (XLRN) and licensed to Celgene (CELG) was further clarified and debated by experts Saturday at a press conference during the American Society of Hematology annual meeting.

The Acceleron drug, called luspatercept, is widely expected to secure approval late next year based on results from two separate Phase 3 clinical trials demonstrating statistically significant reductions in the need for blood transfusions. The patients enrolled in these two studies were diagnosed with myelodysplastic syndrome (MDS), a cancer-like disease of the bone marrow, and beta-thalassemia, a rare inherited disorder that reduces the production of oxygen-carrying hemoglobin.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Great content useful for all the candidates of Data Science training who want to kick start these career in Data Science training field.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy